Abstract
Background: Dendritic cells (DCs) play a crucial role in presenting antigens to T lymphocytes and inducing cytotoxic T cells. DCs have been studied in patients with breast cancer to define the factors leading to failure of an effective systemic and locoregional anticancer host response. Methods: Purified DCs were obtained from peripheral blood (PB) and lymph nodes (LNs) of women with operable breast cancer, using immunomagnetic bead selection. The stimulatory capacity of DCs in the allogeneic mixed leukocyte reaction (MLR) and autologous T cell proliferation test (purified protein derivative (PPD) as stimulator), the expression of surface markers on DCs and the production of cytokines in vitro by DCs from patients with operable breast cancer and from healthy donors (controls) were studied. Results: 70–75% purified DCs were isolated from PB and LNs. PBDCs and LNDCs from patients with operable breast cancer demonstrated a reduced capacity to stimulate in an MLR, compared with PBDCs from normal donors (p<0.01). Autologous T cell proliferation in patients had a decreased ability to respond to PPD, when compared with controls (p<0.01). However, T cells from patients responded as well as control T lymphocytes in the presence of control DCs. PBDCs and LNDCs from patients expressed low levels of HLA-DR and CD86, and induced decreased interleukin-12 (IL-12) secretion in vitro, compared with DCs from normal donors (p<0.01). Conclusion: These data suggest a defective DC function in patients with operable breast cancer. Switched-off DCs in patients with early breast cancer and decreased IL-12 production may be important factors for progressive tumour growth.
Similar content being viewed by others
References
Almand B, Resser JR, Lindman B et al (2000) Clinical significance of defective dendritic cell differentiation in cancer [in process citation]. Clin Cancer Res 6(5):1755
Al-Sarireh B, Robins O, Eremin O (2000) Mononuclear phagocytes but not tumour cells are the main source of elevated interleukin (IL)-10 levels in human breast cancer. J R Coll Surg Edinb 46(1):92
Anton D, Dabadghao S, Palucka K et al (1998) Generation of dendritic cells from peripheral blood adherent cells in medium with human serum. Scand J Immunol 47(2):116
Austyn JM (1998) Dendritic cells. Curr Opin Hematol 5(1):3
Beissert S, Hosoi J, Grabbe S et al (1995) IL-10 inhibits tumor antigen presentation by epidermal antigen- presenting cells. J Immunol 154(3):1280
Bianchi R, Grohmann U, Vacca C et al (1999) Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation. J Immunol 163(5):2517
Brooks CF, Moore M (1988) Differential MHC class II expression on human peripheral blood monocytes and dendritic cells. Immunology 63(2):303
Buelens C, Verhasselt V, De Groote D et al (1997) Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol 27(3):756
Chang JW, Vaquerano JE, Zhou YM et al (1999) Characterization of dendritic cells generated from peripheral blood of patients with malignant melanoma. Anticancer Res 19(3A):1815
Chao D, Bahl P, Houlbrook S et al (1999) Human cultured dendritic cells show differential sensitivity to chemotherapy agents as assessed by the MTS assay. Br J Cancer 81(8):1280
Chaux P, Moutet M, Faivre J et al (1996) Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 74(5):975
Chen B, Shi Y, Smith JD, Choi D (1998) The role of tumor necrosis factor-alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro. Blood 91(12):4652
Clare-Salzler MJ, Brooks J, Chai A et al (1992) Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest 90(3):741
CRC (2001) Information document. Cancer Research UK, London
Damiani D, Stocchi R, Masolini P et al (2002) Dendritic cell recovery after autologous stem cell transplantation. Bone Marrow Transplant 30(5):261
De Smedt T, Van Mechelen M, De Becker G et al (1997) Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 27(5):1229
Enk AH, Angeloni VL, Udey MC, Katz SI (1993) Inhibition of Langerhans cell antigen-presenting function by IL-10: a role for IL-10 in induction of tolerance. J Immunol 151(5):2390
Enk AH, Jonuleit H, Saloga J, Knop J (1997) Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73(3):309
Gabrilovich DI, Patterson S, Harvey JJ et al (1995) Defects in the function of dendritic cells in murine retroviral infection. Adv Exp Med Biol 378:469
Gabrilovich DI, Ciernik IF, Carbone DP (1996) Dendritic cells in antitumor immune responses, I: defective antigen presentation in tumor-bearing hosts. Cell Immunol 170(1):101
Gabrilovich DI, Corak J, Ciernik IF et al (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3(3):483
Garrity T, Pandit R, Wright MA et al (1997) Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer 73(5):663
Grufman P, Karre K (2000) Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur J Immunol 30(4):1088
Hart DN (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90(9):3245
Heufler C, Koch F, Stanzl U et al (1996) Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 26(3):659
Huang YM, Xiao BG, Westerlund I, Link H (1999) Phenotypic and functional properties of dendritic cells isolated from human peripheral blood in comparison with mononuclear cells and T cells. Scand J Immunol 49(2):177
Kabel PJ, de Haan-Meulman M, Voorbij HA et al (1989) Accessory cells with a morphology and marker pattern of dendritic cells can be obtained from elutriator-purified blood monocyte fractions: an enhancing effect of metrizamide in this differentiation. Immunobiology 179(4–5):395
Kelsall BL, Stuber E, Neurath M, Strober W (1996) Interleukin-12 production by dendritic cells: the role of CD40-CD40L interactions in Th1 T-cell responses. Ann N Y Acad Sci 795:116
Knight SC (1986) Non-adherent, low density cells from human peripheral blood contain dendritic cells and monocytes, both with veiled morphology. Immunology 57:595
Koch F, Stanzl U, Jennewein P et al (1996) High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10 [published erratum appears in J Exp Med (1996) 184(4):following 1590]. J Exp Med 184(2):741
Labeur MS, Roters B, Pers B et al (1999) Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 162(1):168
Limpens J, Van Meijer M, Van Santen HM et al (1991) Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative. Immunology 73(3):255
Macatonia SE, Hosken NA, Litton M et al (1995) Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 154(10):5071
Markowicz S, Walewski J, Zajda K et al (2002) Recovery of dendritic cell counts and function in peripheral blood of cancer patients after chemotherapy. Cytokines Cell Mol Ther 7(1):15
Marsh J, Glick B (1992) The effect of cyclophosphamide on bursal and splenic dendritic cells. Poult Sci 71(1):113
McLellan AD, Starling GC, Williams LA et al (1995) Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule [published erratum appears in Eur J Immunol (1995) 25(12):3525]. Eur J Immunol 25(7):2064
Melero I, Duarte M, Ruiz J et al (1999) Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 6(10):1779
Ninomiya T, Akbar SM, Masumoto T et al (1999) Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 31(2):323
Pardoll DM. Cancer vaccines (1998) Nat Med 4[Suppl 5]:525
Pawelec G, Zeuthen J, Kiessling R (1997) Escape from host-antitumor immunity. Crit Rev Oncog 8(2–3):111
Radmayr C, Bock G, Hobisch A et al (1995) Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients. Int J Cancer 63(5):627
Ria F, Penna G, Adorini L (1998) Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells. Eur J Immunol 28(6):2003
Satthaporn S, Eremin O (2001) Dendritic cells, I: biological functions. J R Coll Surg Edinb 46(1):9
Schwaab T, Schned AR, Heaney JA et al (1999) In vivo description of dendritic cells in human renal cell carcinoma [see comments]. J Urol 162(2):567
Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML (1998) High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10(11):1593
Sogn GA (1998) Tumour immunology: the glass is half full. Immunity 9:757
Steinman R, Cohn Z (1973) Identification of a novel cell type in peripheral lymphoid organs of mice. J Exp Med 137:1142
Takahashi K, Asagoe K, Zaishun J et al (1998) Heterogeneity of dendritic cells in human superficial lymph node: in vitro maturation of immature dendritic cells into mature or activated interdigitating reticulum cells. Am J Pathol 153(3):745
Thurnher M, Radmayr C, Ramoner R et al (1996) Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 68(1):1
Voorhis WC (1982) Human dendritic cells: enrichment and characterisation from peripheral blood. J Exp Med 155:1172
Xu H, Friedrichs U, Gieseler RK et al (1992) Human blood dendritic cells exhibit a distinct T-cell-stimulating mechanism and differentiation pattern. Scand J Immunol 36(5):689
Young JW, Steinman RM (1988) Accessory cell requirements for the mixed-leukocyte reaction and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells. Cell Immunol 111(1):167
Zambruno G, Girolomoni G, Manca V et al (1992) Epidermal Langerhans cells after allogeneic bone marrow transplantation: depletion by chemotherapy conditioning regimen alone. J Cutan Pathol 19(3):187
Zou JP, Shimizu J, Ikegame K (1992) Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity. J Immunol 148:648
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Satthaporn, S., Robins, A., Vassanasiri, W. et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 53, 510–518 (2004). https://doi.org/10.1007/s00262-003-0485-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-003-0485-5